Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
Menu
Articles
Author Correction
Autoimmune Diseases
Cardiovascular Conditions
Commentary
Correspondence
Dermatological Diseases
Endocrine Diseases
Gastrointestinal Conditions
General Indications
Hematology
Hereditary Genetic Disorders
Infectious Diseases
Methodology and Healthcare Policy
Nephrologic/Hepatologic Conditions
Neurological Diseases
Oncology
Ophthalmology
Other Conditions
Perspective
Psychological Conditions
Respiratory Diseases
Trauma Induced Conditions
Urological/Gynecological Diseases
All
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers
search
Sorry, something went wrong. Please try your search again.
×
Articles
Blog posts
RSS Feed
Enter the URL below into your favorite RSS reader.
https://jheor.org/feed
×
Dermatological Diseases
Vol. 2, Issue 1, 2014
October 01, 2014 EDT
Willingness-to-pay to access Ingenol Mebutate Gel for Actinic Keratosis Treatment in the U.S. Setting
Michael Willis
,
Sandra Erntoft
,
Sofie Persson
,
Jenny M. Norlin
,
Ulf Persson
,
topical agents
contingent valuation
patient preferences
local skin reactions
actinic keratosis
willingness-to-pay
Copyright Logo
ccby-4.0
•
https://doi.org/10.36469/9879
JHEOR
1.
Willis M, Erntoft S, Persson S, Norlin JM, Persson U. Willingness-to-pay to access Ingenol Mebutate Gel for Actinic Keratosis Treatment in the U.S. Setting.
JHEOR
. 2014;2(1):1-14.
doi:10.36469/9879
Save article as...
▾
PDF
XML
Citation (BibTeX)
View more stats